A randomized; double blind; placebo-controlled study to evaluate the impact of Nilotinib treatment on safety; tolerability; pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)
A randomized; double blind; placebo-controlled study to evaluate the impact of Nilotinib treatment on safety; tolerability; pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)